Infectious disease point-of-care test (ID-POCT) devices are becoming widely available, and in this respect, international quality standards and guidelines are available for consultation once ID-POCT has been implemented into medical institutions. However, specific guidelines for consultation during the initial pre-implementation decision-making process are currently lacking. Further, there exist pre-implementation issues specific to ID-POCT. Here we present pre-implementation guidelines for consultation when considering the implementation of ID-POCT in medical institutions. ID-POCT01-A2 'Point-of-Care Connectivity' -Approved Standard-Second Edition [5] and 'Diagnosing Infection at the Point of Care' [6] etc. However, the implementation of dedicated infectious disease POCT (ID-POCT) devices into medical institutions tends to lag behind that of POCT devices used in many other medical disciplines, for example, clinical chemistry. Further, though many of the implementation issues for POCT and ID-POCT are similar (see references above), there still exist crucial pre-implementation differences between POCT and ID-POCT before their implementation into medical institutions [7][8] [9] .
Point-of-care test (POCT) devices are widely available for use in medical institutions [1] and in this respect, international quality standards and guidelines are available regarding their implementation ID-POCT01-A2 'Point-of-Care Connectivity' -Approved Standard-Second Edition [5] and 'Diagnosing Infection at the Point of Care' [6] etc. However, the implementation of dedicated infectious disease POCT (ID-POCT) devices into medical institutions tends to lag behind that of POCT devices used in many other medical disciplines, for example, clinical chemistry. Further, though many of the implementation issues for POCT and ID-POCT are similar (see references above), there still exist crucial pre-implementation differences between POCT and ID-POCT before their implementation into medical institutions [7] [8] [9] .
One of the hurdles to implementing ID-POCT is a lack of specific ID-POCT guidelines and solutions which can be used to guide ID-POCT stakeholders, for example, physicians, laboratory managers, ID-POCT manufacturers and retailers, financial personnel etc. in their decision making before actual implementation issues are decided. Further, there exist specific ID-POCT pre-implementation issues which may not be applicable to other forms of POCT devices.
In this Perspective article, the authors present a simple and 'holistic' set of ID-POCT guidelines that can be used by ID-POCT stakeholders to guide their pre-implementation ID-POCT decision-making processes within their own medical institutions. In this respect, 'holistic' means taking into account the whole range of stakeholders involved in the implementation of ID-POCT within medical institutions, including clinicians, diagnosticians, laboratory managers, healthcare financiers, manufacturers of ID-POCT and patients (specifically the actual clinical needs of the PersPective van der Eijk, Tintu & Hays future science group patient). By including all of these stakeholders in the decision-making process, informed and accurate decisions can be made regarding the needs and usefulness of ID-POCT within individual medical institutions. These guidelines are based on the experiences of a recently established point-of-care expert group at the Erasmus University Medical Center Rotterdam (Erasmus MC), a tertiary care university medical center based in Rotterdam, the Netherlands, with approximately 1,220 hospital beds, and which receives approximately 40,000 in-patients and 500,000 out-patient visits per year. The guidelines will be useful to both medical institutions and ID-POCT kit manufacturers and encourage these organizations (with potentially conflicting goals) to better understand and interact with one another in order to achieve the successful implementation of ID-POCT into existing analytical workflows within medical institutions. Although the intention of this article is to present a 'universal' set of guidelines, it should be noted that not all of the suggestions made may be applicable to all healthcare providers in all countries and
Preferred route Alternative routes
Establish an internal ID-POCT work group:
Create and circulate a ID-POCT questionnaire:
Recruit expert representatives from key departments for which POCT testing is (or is likely to be) used within your medical institution. Try to create a 'holistic' internal POCT working group which includes clinicians, diagnosticians, laboratory managers, financiers etc.
Interpret the results and generate advice for circulation to potential POCT users within the medical institution.
Act on this advice e.g. by creating informational presentations, including on the advantages and disadvantages of POCT.
Create dissemination pipelines for POCT information internally (also Table 1 ).
'Pro-actively' develop contacts with ID-POCT manufacturers:
The internal ID-POCT working group should be the first line of contact between ID-POCT manufacturers and individual medical institutions (also Tables 3 & 4) .
ID-POCT manufacturers possess useful evaluation, validation and implementation data.
Generate 'selection' and 'implementation' criteria:
Criteria can be individually prioritized dependent on the local requirements of each medical institution (also Tables 2 & 4) .
The size and composition of medical personnel employed at different medical institutions e.g. the ratio of doctors, nurses, diagnosticians, technicians etc, may influence the prioritization of the institutional selection criteria.
How will ID-POCT interact with current laboratory management information systems (LIMS)?
Patient safety and data security? Establish an internal pilot study for comparison with current 'gold standard' test.
ID-POCT management and quality control and quality assurance procedures:
A standardized and regular quality control/assurance scheme should be implemented within the institution to monitor and ensure the maintenance of, or improvements in, current standards of patient care (also Tables 3 & 4) .
Training of relevant personnel in the use of ID-POCT is essential.
future science group www.futuremedicine.com adaptation of the guidelines may be necessary in order to meet with local or national requirements.
An 'overview of the ID-POCT pre-implementation process' per se is shown in Figure 1 , including several 'alternative routes' that may be taken dependent on individual circumstances within different medical institutions. For the implementation of ID-POCT on a small scale i.e. institutions with only one or two medical departments, creating and circulating an ID-POCT questionnaire may not be necessary as the opinions of end-users can be simply obtained via face-to-face discussions. However, this particular alternative route is not recommended for larger medical institutions, or where there is a debate regarding which particular ID-POCT device is most suitable for implementation. Similarly, it is not absolutely necessary to develop contacts with ID-POCT manufacturers for the small-scale use of ID-POCT. However, ID-POCT manufacturers can be a good source of rapid information regarding new developments for their particular ID-POCT device, and if large quantities of consumables will be required for a particular ID-POCT, then it may be possible to negotiate financial discounts, especially if there is the possibility of competition between two or more ID-POCT companies for your business.
tables 1-3 and Box 1 provide more detail to Figure 1 and group the guidelines into general themes relating to: suggested 'dissemination pipelines' (table 1) -essentially, knowledge gathering and knowledge dissemination guidelines in order to understand and react to the needs and perceptions of ID-POCT stakeholders, thereby providing a broad base on which to build ID-POCT implementation discussions; potential 'selection criteria' (Box 1) -considerations which may be relevant to ID-POCT stakeholders in different medical institutions; 'pro-active' interactions (table 2) -generating institution-specific ID-POCT purchase and implementation guidelines; and ID-POCTspecific pre-implementation issues (table 3) -there are several ID-POCT preimplementation issues which are particularly important for certain types of ID-POCT devices and situations.
Consultation and/or adoption of these guidelines will establish a firm foundation for the table 1. suggested 'dissemination pipelines' for distributing institutional infectious disease point-of-care test information (both internally and externally).
Pipeline comments
Institution-wide 'intranet site' and or 'service portal'
• What potentially appropriate ID-POCT are available within and outside the medical center?
• Keep up-to-date with new advances in the market
Create a dedicated institutional ID-POCT website where colleagues can obtain ID-POCT information when they need it (a simple website could be created with links to external sources of information [10] )
• Include these guidelines, implementation costs, quality control issues, etc
• Create an internal ID-POCT discussion forum • Publish your own findings regarding quality of ID-POCT devices, for example, sensitivity, specificity etc Determine consequences of ID-POCT testing on current and future research and education activities (applicable to medical institutions with academic responsibilities) Effect of ID-POCT on the maintenance of up-to-date and state-of-theart teaching and training programs in the rapidly changing field of medical diagnostics Prepare standard communication texts -leaflets etc. -informing patients of the advantages and disadvantages of using (a specific) ID-POCT Patients should be considered as stakeholders and therefore informed over the reasons for implementing ID-POCT (particularly in comparison with current 'gold standard' laboratory-based techniques) ID-POCT: Infectious disease point-of-care test.
PersPective van 
successful implementation of ID-POCT within many different types of medical institutions. Further, ID-POCT assay manufacturers will receive the opportunity to pro-actively inform and interact at all stages within the ID-POCT implementation process. However, it should be noted that such interactions should be mutually beneficial and ideally based on solid scientific evidence or previous implementations of ID-POCT assays into the medical environment, rather than simply being a 'lobbying' or 'sales' exercise by individual ID-POCT assay manufacturers/developers to individual medical institutions. The large scale successful implementation of ID-POCT in medical institutions could ultimately be beneficial for all ID-POCT stakeholders, including clinicians, diagnosticians, laboratory managers, healthcare providers and (most importantly) patients themselves.
Finally, it should be noted that the main emphasis of these guidelines has been directed toward the implementation of ID-POCT within medical institutions per se, rather than the development of guidelines for the use of (disposable) ID-POCT in: 'low experience' environments, for example, patients at home; 'extreme' environments, for example, battlefield situations, astronauts in space etc. or 'limited resource' environments, for example, in developing countries during infectious disease epidemics (Ebola, Zika viruses, Enterohemorrhagic Escherichia coli food-borne disease outbreaks etc.) where medical personnel may be at special risk of (nosocomial) infection or staff shortages may occur. However, this does not mean that the above guidelines are invalid for these situations, rather that individual guidelines may have to be adapted, ignored or some guidelines given more 'weight' than other guidelines in order to best serve the requirements of the individual situation, for example, user education, urgency of the situation; explosive increase in ID-POCT throughput requirements, ID-POCT component stability, ID-POCT costs etc. Ultimately, it is the choice of the (end) user who will determine which guidelines are useful for their own p articular situation. conclusion POCT has the potential to transform current healthcare practices. However, (pre-)implementation issues may be limiting the introduction and successful use of POCT within many medical environments and institutions. This [12] future science group www.futuremedicine.com Box 1. List of potential 'selection criteria' for consideration prior to infectious disease point-of-care test implementation.
Technology
• The extent to which the technology:
• Is valuable and affordable • Has been evaluated -including in the scientific literature -with respect to specimen collection, specificity, sensitivity, reproducibility, cost per test etc
• Fits within the existing IT infrastructure (e.g., security, bandwidth)
• Requires certification (appropriate for regional, national or international regulations where the ID-POCT will be performed)
• Is applicable to the work environment, for example, hospital general wards, emergency rooms, family doctors' offices
Implementation
• Is the test approved for use by (inter)national regulatory authorities?
• The simplicity of complying with existing laws and regulations • The extent to which the new service can be incorporated into existing workflows • Are the appropriate resources available (including extra laboratory capacity)?
• The degree to which the risks associated with implementation can be controlled • The speed at which the new ID-POCT test service can be launched • Cultural barriers -perceived lack of confidentiality and individual/societal stigma associated with the result, for example, HIV rapid tests
Use and alternatives
• The degree of acceptance by medical institution care providers and customers/clients for this kind of service is especially true for ID-POCT. Therefore, in this publication, the authors provide preimplementation guidelines for consideration by ID-POCT stakeholders, including healthcare workers, laboratory managers, financiers and POCT developers, when deciding on the possible implementation of ID-POCT within medical institutions.
Future perspective
The implementation of ID-POCT offers much potential, but currently lags behind the • Are healthcare providers willing to pay for the costs of these extra tests (compared to the use of a single target-specific ID-POCT), even if these are not requested by the clinician? Quality control and quality assurance of ID-POCT multiple target detection devices is more complex than single target POCT
• How often should each target be QC/QA? If an ID-POCT can detect 20 targets simultaneously, should all 20 targets receive QC/QA at the same time? If a target only receives QC/QA once every 3 months, instead of for example once every month, then many more patients may have to be informed that their test results were incorrect if that 3 monthly test fails. This could lead to higher morbidity and mortality compared to a ID-POCT which receives QC/QA every week or month
• What are the extra costs involved in the quality control/quality assurance of multi-target ID-POCT?
• Is there a reliable supplier of reference material for each of the targets in a multi-target ID-POCT?
• Will healthcare providers be willing to pay for additional QC/QA testing for rare, or unused targets?
• Sample collection and storage issues should be discussed, agreed and implemented in order to provide a biobank of duplicate patient samples in case quality control procedures indicate that the ID-POCT has failed Potential use of emergency legislation in times of biological crises Be aware of emergency legal issues, for example, the US FDA EUA. "Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by chemical, biological, radiological and nuclear defence threat agents, when there are no adequate, approved, and available alternatives" [13, 14] Provision of personal protective equipment, high risk testing, and isolation units
The explosive spread of highly infectious agents e.g. Zika, Ebola, MERS-CoV, may require the rapid implementation of ID-POCT. Suitable protocols, training and equipment need to be available in order to ensure the success of the rapid implementation of ID-POCT, especially if these tests do not form part of the 'normal' diagnostic packet of medical institutions Access to reference material Currently, specimens sent to microbiology laboratories for the detection of infectious disease pathogens provide an extremely useful resource for epidemiological studies, as well as being a source of novel microbial pathogens. If ID-POCT becomes widely used in hospital wards, at family doctor practices, or even at home, what will the effect be on the successful tracking and surveillance of microbial pathogens? Think for example about the yearly production of an effective influenza vaccine, or the efficient monitoring of carbapenem antibiotic resistance in Europe Universal primers In order to provide broad coverage for the detection of a specific microbial pathogen, ID-POCT tend to use primers directed against universal sequences that are present within all known members of a particular microbial species. This means that there will be much less information available regarding the epidemiology of specific microbial strains compared with, for example a 'catch-all' technique such as bacterial culture (where bacteria can be cultured and their specific epidemiological profiles determined by further processing e.g. gene sequencing) Next generation sequencing ID-POCT
• One exception to the 'access to reference material' and 'universal primers' comments mentioned above, is the use of next-generation sequencing-based ID-POCT, which could provide specific epidemiological information on the target pathogen detected. However, there may be potentially multiple pathogens present within a clinical sample and the experience of clinicians may be required in order to determine which potential pathogen is associated with the current disease state
• Next-generation sequencing ID-POCT may require intensive bioinformatics and software support, which means that this kind of test may not be (currently) suitable for applications outside of secondary or tertiary care medical institutions. Additionally, algorithms will need to be developed which simulate the 'experience of clinicians' when making decisions regarding the relative contribution of a potential pathogen to the current disease state EUA: Emergency use authorization; ID-POCT: Infectious disease point-of-care test; QA: Quality assured; QC: Quality control.
